Pharmaxis (ASX:PXS) Stock Price Down 2.6%
Pharmaxis Ltd. (ASX:PXS) shares dropped 2.6% on Friday . The company traded as low as A$0.19 ($0.13) and last traded at A$0.19 ($0.13), approximately 166,319 shares changed hands during mid-day trading. A decline of 49% from the average daily volume of 328,880 shares. The stock had previously closed at A$0.19 ($0.13).
The firm has a market cap of $72.99 million and a PE ratio of -3.49. The company has a quick ratio of 4.72, a current ratio of 5.00 and a debt-to-equity ratio of 48.41. The stock’s fifty day simple moving average is A$0.22 and its two-hundred day simple moving average is A$0.25.
In other news, insider Gary Phillips 379,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th.
Pharmaxis Ltd engages in the research, development, and commercialization of human healthcare products for the treatment and management of chronic diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness.
Further Reading: What is channel trading?
Receive News & Ratings for Pharmaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmaxis and related companies with MarketBeat.com's FREE daily email newsletter.